These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma. Mizutani Y; Iida T; Ohno E; Ishikawa T; Kinoshita F; Kuwatsuka Y; Imai M; Shimizu S; Tsuruta T; Enomoto A; Kawashima H; Fujishiro M BMC Cancer; 2022 Feb; 22(1):205. PubMed ID: 35209871 [TBL] [Abstract][Full Text] [Related]
3. Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Ichihara R; Shiraki Y; Mizutani Y; Iida T; Miyai Y; Esaki N; Kato A; Mii S; Ando R; Hayashi M; Takami H; Fujii T; Takahashi M; Enomoto A Pathol Int; 2022 Mar; 72(3):161-175. PubMed ID: 35020975 [TBL] [Abstract][Full Text] [Related]
4. Meflin is a marker of pancreatic stellate cells involved in fibrosis and epithelial regeneration in the pancreas. Ando R; Shiraki Y; Miyai Y; Shimizu H; Furuhashi K; Minatoguchi S; Kato K; Kato A; Iida T; Mizutani Y; Ito K; Asai N; Mii S; Esaki N; Takahashi M; Enomoto A J Pathol; 2024 Jan; 262(1):61-75. PubMed ID: 37796386 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. Iida T; Mizutani Y; Esaki N; Ponik SM; Burkel BM; Weng L; Kuwata K; Masamune A; Ishihara S; Haga H; Kataoka K; Mii S; Shiraki Y; Ishikawa T; Ohno E; Kawashima H; Hirooka Y; Fujishiro M; Takahashi M; Enomoto A Oncogene; 2022 May; 41(19):2764-2777. PubMed ID: 35414659 [TBL] [Abstract][Full Text] [Related]
6. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030 [TBL] [Abstract][Full Text] [Related]
7. Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin/Islr in Cancer Fibrosis. Takahashi M; Kobayashi H; Mizutani Y; Hara A; Iida T; Miyai Y; Asai N; Enomoto A Front Cell Dev Biol; 2021; 9():749924. PubMed ID: 34676218 [TBL] [Abstract][Full Text] [Related]
8. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078 [TBL] [Abstract][Full Text] [Related]
9. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Djurec M; Graña O; Lee A; Troulé K; Espinet E; Cabras L; Navas C; Blasco MT; Martín-Díaz L; Burdiel M; Li J; Liu Z; Vallespinós M; Sanchez-Bueno F; Sprick MR; Trumpp A; Sainz B; Al-Shahrour F; Rabadan R; Guerra C; Barbacid M Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1147-E1156. PubMed ID: 29351990 [TBL] [Abstract][Full Text] [Related]
10. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Miyai Y; Sugiyama D; Hase T; Asai N; Taki T; Nishida K; Fukui T; Chen-Yoshikawa TF; Kobayashi H; Mii S; Shiraki Y; Hasegawa Y; Nishikawa H; Ando Y; Takahashi M; Enomoto A Life Sci Alliance; 2022 Jun; 5(6):. PubMed ID: 35236758 [TBL] [Abstract][Full Text] [Related]
11. Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin in Cardiac Tissue Repair and the Development of Diastolic Dysfunction. Hara A; Kobayashi H; Asai N; Saito S; Higuchi T; Kato K; Okumura T; Bando YK; Takefuji M; Mizutani Y; Miyai Y; Saito S; Maruyama S; Maeda K; Ouchi N; Nagasaka A; Miyata T; Mii S; Kioka N; Worthley DL; Murohara T; Takahashi M; Enomoto A Circ Res; 2019 Aug; 125(4):414-430. PubMed ID: 31221024 [TBL] [Abstract][Full Text] [Related]
12. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. Kawase T; Yasui Y; Nishina S; Hara Y; Yanatori I; Tomiyama Y; Nakashima Y; Yoshida K; Kishi F; Nakamura M; Hino K BMC Gastroenterol; 2015 Sep; 15():109. PubMed ID: 26330349 [TBL] [Abstract][Full Text] [Related]
13. Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model. Miyazaki Y; Oda T; Inagaki Y; Kushige H; Saito Y; Mori N; Takayama Y; Kumagai Y; Mitsuyama T; Kida YS Sci Rep; 2021 Feb; 11(1):4690. PubMed ID: 33633222 [TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives. Miyai Y; Esaki N; Takahashi M; Enomoto A Cancer Sci; 2020 Apr; 111(4):1047-1057. PubMed ID: 32060987 [TBL] [Abstract][Full Text] [Related]
15. BNIP3+ fibroblasts associated with hypoxia and inflammation predict prognosis and immunotherapy response in pancreatic ductal adenocarcinoma. Gao B; Hu G; Sun B; Li W; Yang H J Transl Med; 2024 Oct; 22(1):937. PubMed ID: 39402590 [TBL] [Abstract][Full Text] [Related]